Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
Christian BuskeAlessandra TedeschiJudith TrotmanMiriam SanteroDavid MacDonaldVeronique LeblondBeatrice MaheCharles HerbauxJeffrey V MatousConstantine S TamLeonard T HeffnerMarzia VarettoniMaria Lia PalombaChaim ShustikEfstathios KastritisSteven P TreonJerry PingBernhard HaunsIsrael Arango-HisijaraMeletios- Athanasios DimopoulosPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
In the final analysis of iNNOVATE with a median follow-up of 50 months, ibrutinib-rituximab showed ongoing superiority across clinical outcomes in patients with WM regardless of MYD88 or CXCR4 mutation status, prior treatment, and key patient characteristics.